Brought to you by 
Roche pens companion test deal with Psynova, RBM
27 May 2011
Executive Summary
Rules-Based Medicine (RBM; multiplexed immunoassay technologies) and its neuropsychiatric biomarkers subsidiary Psynova Neurotech have signed an exclusive agreement with Roche to develop companion diagnostic immunoassays for one the of Big Pharma's neurology drug candidates.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche pens companion test deal with Psynova, RBM
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice